메뉴 건너뛰기




Volumn 10, Issue 12, 2010, Pages 1233-1234

Cabazitaxel: Filling one of the gaps in the treatment of prostate cancer

Author keywords

Cabazitaxel; Castrate resistant; Chemotherapy; FDA approval; Metastatic cancer; Prostate cancer; Survival; Taxane

Indexed keywords

CABAZITAXEL; DOCETAXEL; IXABEPILONE; MITOXANTRONE; PREDNISONE; SATRAPLATIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

EID: 78650389128     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.12.14085     Document Type: Article
Times cited : (7)

References (15)
  • 3
    • 38349167518 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
    • Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5.
    • (2008) J Clin Oncol , vol.26 , pp. 242-245
    • Berthold, D.R.1    Pond, G.R.2    Soban, F.3    De Wit, R.4    Eisenberger, M.5    Tannock, I.F.6
  • 4
    • 0032784113 scopus 로고    scopus 로고
    • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
    • Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-13.
    • (1999) J Clin Oncol , vol.17 , pp. 2506-2513
    • Kantoff, P.W.1    Halabi, S.2    Conaway, M.3    Picus, J.4    Kirshner, J.5    Hars, V.6
  • 5
    • 8944220720 scopus 로고    scopus 로고
    • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
    • Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-64.
    • (1996) J Clin Oncol , vol.14 , pp. 1756-1764
    • Tannock, I.F.1    Osoba, D.2    Stockler, M.R.3    Ernst, D.S.4    Neville, A.J.5    Moore, M.J.6
  • 6
    • 29944434214 scopus 로고    scopus 로고
    • Therapeutic options in androgen-independent prostate cancer: Building on docetaxel
    • Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU international 2005; 96:41-6.
    • (2005) BJU International , vol.96 , pp. 41-46
    • Petrylak, D.1
  • 7
    • 77951644363 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer
    • Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:2070-6.
    • (2010) J Clin Oncol , vol.28 , pp. 2070-2076
    • Ning, Y.M.1    Gulley, J.L.2    Arlen, P.M.3    Woo, S.4    Steinberg, S.M.5    Wright, J.J.6
  • 8
    • 4344682179 scopus 로고    scopus 로고
    • Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
    • Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-9.
    • (2004) J Clin Oncol , vol.22 , pp. 2532-2539
    • Dahut, W.L.1    Gulley, J.L.2    Arlen, P.M.3    Liu, Y.4    Fedenko, K.M.5    Steinberg, S.M.6
  • 9
    • 34547119271 scopus 로고    scopus 로고
    • Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
    • Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110:556-63.
    • (2007) Cancer , vol.110 , pp. 556-563
    • Rosenberg, J.E.1    Weinberg, V.K.2    Kelly, W.K.3    Michaelson, D.4    Hussain, M.H.5    Wilding, G.6
  • 10
    • 73949098659 scopus 로고    scopus 로고
    • Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial
    • Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, et al. Multinational, doubleblind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27:5431-8.
    • (2009) J Clin Oncol , vol.27 , pp. 5431-5438
    • Sternberg, C.N.1    Petrylak, D.P.2    Sartor, O.3    Witjes, J.A.4    Demkow, T.5    Ferrero, J.M.6
  • 11
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-54.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3    Hansen, S.4    MacHiels, J.P.5    Kocak, I.6
  • 13
    • 50849088935 scopus 로고    scopus 로고
    • A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
    • Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547-52.
    • (2008) Ann Oncol , vol.19 , pp. 1547-1552
    • Pivot, X.1    Koralewski, P.2    Hidalgo, J.L.3    Chan, A.4    Goncalves, A.5    Schwartsmann, G.6
  • 14
    • 59449102526 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
    • Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-30.
    • (2009) Clin Cancer Res , vol.15 , pp. 723-730
    • Mita, A.C.1    Denis, L.J.2    Rowinsky, E.K.3    Debono, J.S.4    Goetz, A.D.5    Ochoa, L.6
  • 15
    • 77957665460 scopus 로고    scopus 로고
    • Cabazitaxel in prostate cancer: Stretching a string
    • Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010; 376:1119-20.
    • (2010) Lancet , vol.376 , pp. 1119-1120
    • Dorff, T.B.1    Quinn, D.I.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.